Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M406613200 on November 29, 2004

J. Biol. Chem., Vol. 280, Issue 5, 3493-3499, February 4, 2005
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/5/3493    most recent
M406613200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brusselmans, K.
Right arrow Articles by Dewerchin, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brusselmans, K.
Right arrow Articles by Dewerchin, M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

A Novel Role for Vascular Endothelial Growth Factor as an Autocrine Survival Factor for Embryonic Stem Cells during Hypoxia*

Koen Brusselmans{ddagger}, Françoise Bono§, Désiré Collen{ddagger}, Jean-Marc Herbert§, Peter Carmeliet{ddagger}, and Mieke Dewerchin{ddagger}

From the {ddagger}Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology (VIB), KULeuven, Leuven, B-3000, Belgium and§Sanofi~Aventis Recherche, Cardiovascular/Thrombosis Research Department, Toulouse Cedex F31036, France

Received for publication, June 14, 2004 , and in revised form, November 22, 2004.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Vascular endothelial growth factor (VEGF) is best known for its angiogenic activity on endothelial cells, but it also affects neurons, pneumocytes, and other mature cell types as well as endothelial, neural, and hematopoietic progenitors. Here, we examined its effect on pluripotential embryonic stem (ES) cells under hypoxic stress. ES cells were found to produce VEGF and to express VEGF receptor-2 and neuropilin-1 (Nrp-1), a VEGF165 isoform-specific receptor. During hypoxia, expression levels of VEGF, Flk-1, and Nrp-1 were elevated. Inhibition or targeted gene inactivation of VEGF increased ES cell apoptosis during prolonged hypoxia (48 h) by about 10-fold. The survival activity of VEGF was specific since inhibition of other growth factors (including basic fibroblast growth factor, epidermal growth factor, insulin-like growth factor, platelet-derived growth factor, and placental growth factor) had no effect. Neuropilin-1 was involved in the VEGF-survival activity since overexpression of Nrp-1 decreased hypoxia-induced apoptosis about 3-fold. The hypoxia-response element, via which hypoxia-inducible transcription factors up-regulate VEGF expression under hypoxic conditions, was critical since targeted deletion of this element in the VEGF promoter enhanced hypoxia-induced ES cell apoptosis to the same extent as VEGF inhibition or gene inactivation. Thus, VEGF plays a critical role in survival of ES cells during prolonged hypoxia.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Blood vessels are critical for delivery of oxygen to growing mammalian tissues. Certain tissues such as the cornea and cartilage in the adult remain avascular and receive oxygen from diffusion of nearby blood vessels, as vessels would impede transmission of light or cause bleeding of joints, respectively. During development, the oocyte in the ovarian follicle receives oxygen through diffusion from perifollicular blood vessels through the follicular fluid, whereas the oxygen needed for cellular metabolism and division of the preimplantation embryo is supplied by diffusion from the fluids within the oviduct and uterus, respectively. Development of the early pre-implantation embryo therefore occurs in an environment with reduced oxygenation until the onset of vascularization after blastocyst implantation (1, 2). The mechanisms responsible for the adaptation of the blastocyst to hypoxic damage remain poorly characterized.

A particular growth factor that plays an essential role in the cellular adaptation to hypoxia is vascular endothelial growth factor (VEGF),1 one of the most important prototype angiogenic factors in health and disease (3–5). It is alternatively transcribed in different VEGF isoforms, which bind to VEGF receptor-2 (also named fetal liver kinase-1 (Flk-1) or kinase insert domain-containing receptor (KDR)) and VEGF receptor-1 (also named fms-like tyrosine kinase-1 (Flt-1)) (6, 7). The VEGF165 isoform, which is sufficient for normal vascular development (8–10), binds to neuropilin-1 (Nrp-1), a receptor for the collapsin/semaphorin family expressed on neuronal, endothelial, and hematopoietic cells (11–13). VEGF is rapidly and significantly up-regulated in response to hypoxia via activation of the hypoxia-inducible transcription factors HIF-1{alpha} and HIF-2{alpha}, which bind to the hypoxia-response element (HRE) in the VEGF promotor (14), leading to angiogenesis and restoration of tissue oxygenation.

Recent studies also indicated that VEGF may protect cells against hypoxic damage by directly stimulating their survival, independently of angiogenesis. For instance, VEGF appeared to be critical to prevent motor neuron degeneration, not only because it was essential to maintain sufficient perfusion but also because it exerted direct trophic effects on neuronal survival (15–17). Because VEGF not only affects differentiated cell types but also adult precursors of several lineages including endothelial and neural progenitor cells, which express Flk-1, and hematopoietic stem cells, which express Flt-1 (18–20), we examined in the present study whether VEGF also affects embryonic stem (ES) cells, the equivalent of the pluripotential inner cell mass of blastocysts. Because ES cells constitute a potential renewable source of progenitors for tissue regeneration via cellular transplantation (21, 22), a better understanding of the mechanisms protecting such stem cells against environmental stress is warranted. Our findings indicate that ES cells during prolonged hypoxia produce elevated levels of VEGF and its receptors Flk-1 and Nrp-1 via mechanisms involving the hypoxia-inducible transcription factors. Using genetic and pharmacological analyses, we uncover a novel role for VEGF as a survival factor for ES cells in hypoxia.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Targeted ES Cell Clones and Materials—ES cells deficient in VEGF (VEGF–/–), HIF-1{alpha} (HIF-1{alpha}–/–), or PlGF (PlGF–/–) were generated by homologous recombination and subsequent selection in high G418, as described previously (3, 23, 24). Mutation of the HIF-1{alpha} binding site in the VEGF promoter and generation of homozygous mutant (VEGF{delta}/{delta}) ES cells by selection in high G418 has been described in detail elsewhere (15). VEGF, basic fibroblast growth factor (bFGF), platelet-derived growth factor-BB (PDGF-B), insulin-like growth factor-1 (IGF-1), epidermal growth factor (EGF) and PlGF, and monoclonal antibodies against VEGF, bFGF, PDGF-B, IGF-1, EGF, or PlGF were purchased from R&D (Abingdon, UK). Leukemia inhibitory factor (LIF; ESGRO) was from Chemicon International (Temecula, CA). Culture media and reagents were from Invitrogen, HyClone (Logan, UT), and Roche Applied Science.

Hypoxic Treatment of ES Cells—Undifferentiated ES cells were cultured in 75-cm2 flasks or 10-cm culture dishes on mitomycin C-treated embryonic fibroblasts in Dulbecco's modified Eagle's medium containing 15% heat-inactivated fetal calf serum, 100 IU/ml penicillin, 100 µg/ml streptomycin, 2 mM glutamine, and 20 ng/ml LIF. ES cells were detached with 0.05% trypsin and 0.02% EDTA and seeded at low cell density (10,000 cells/35-mm Petri dish, precoated for at least 24 h with 0.2% gelatin) in culture medium supplemented with 20 ng/ml LIF and 5% fetal calf serum. After 24 h ES cells were rinsed with phosphate-buffered saline, and fresh culture medium supplemented with 5% fetal calf serum but without LIF was added. Experiments were performed in an incubator at 37 °C under normoxia (N) by maintaining the cells in 95% air and 5% CO2 or under hypoxia (H; 0.5% O2) by incubating cells in a humidified sealed chamber gassed with 0.5% O2,5%CO2, and 94.5% N2 (AGA, Lille, France) at a flow rate of 30 liters/h for 24 to 48 h. After incubation in normoxia or hypoxia for 24 or 48 h, ES cells were analyzed for apoptosis or used for Northern blot analysis as described below. Growth factors and antibodies were added to the culture medium as indicated.

Measurement of Apoptosis—Apoptosis of ES cells was measured (every 12 h) during a 24- or 48-h (prolonged) incubation with a photometric enzyme immunoassay (cell detection enzyme-linked immunosorbent assay, Roche Applied Science) for quantitation of cytoplasmic histone-associated DNA fragments (mono- and oligonucleosomes) (23). First, ES cells grown under normoxia or hypoxia as described above were rinsed with phosphate-buffered saline to remove the floating dead cells. Subsequently, ES cells were detached and assayed for apoptosis, which was expressed as the average number of oligonucleosomes per 105 cells. Terminal deoxytransferase-mediated deoxyuridine nick end-labeling of cultured ES cells was performed using a commercially available kit according to the manufacturer's instructions (Trevigen, Gaithersburg, MD).

Expression of VEGF, PlGF, and Their Receptors—VEGF in ES cell-conditioned medium was measured at the indicated times by enzyme-linked immunosorbent assay (R&D). For Northern blot analysis, total RNA isolated from 5 x 106 cells cultured for 24 h was prepared and hybridized as described previously (3, 23). Hybridization probes were used for VEGF (a 655-bp BamHI-EcoRI fragment encompassing the entire open reading frame of the murine VEGF188 isoform cDNA), for PlGF (a 1391-bp NotI-XhoI fragment, encompassing the entire open reading frame), for VEGF receptor-1 (VEGFR-1 or Flt-1) (a PCR fragment encompassing nucleotides 421–1403 of the murine VEGFR-1 cDNA), for VEGF receptor-2 (VEGFR-2 or Flk-1) (a PCR fragment encompassing nucleotides 3361–4440 of the murine VEGFR-2 cDNA), and for neuropilin-1 (Nrp-1) (a PCR fragment encompassing nucleotides 358–761 of the murine Nrp-1 cDNA).

Neuropilin-1 Overexpression in WT ES Cells—WT ES cells were electroporated with a plasmid bearing the human neuropilin-1 (NRP-1) gene under control of a cytomegalovirus promoter and the hygromycin phosphotransferase gene as a selection marker. WT ES cells transfected with a control plasmid only bearing the selection marker were used as controls. Overexpression of NRP-1 was quantified by reverse transcription-PCR as the number of mRNA copies per 100 mRNA copies of hypoxanthine guanine phosphoribosyltransferase. Total RNA was extracted from ES cells using TRIZOL reagent (Invitrogen) and reverse-transcribed with Superscript II (Invitrogen). Quantitative real time reverse transcription-PCR was performed according to the manufacturer's protocol (PerkinElmer Life Sciences) using the following forward and reverse primer and probe (P), labeled with fluorescent dye (FAM or JOE) and quencher (TAMRA) as described previously (8): for NRP-1 forward, 5'-TGTGAAGTGGAAGCCCCTACA-3'; reverse, 5'-GGCCTGGTCGTCATCACATT-3'; probe, 5'-FAM-CCGACCACTCCCAACGGGAACTTG-TAMRA3'; for hypoxanthine guanine phosphoribosyltransferase forward, 5'-TTATCAGACTGAAGAGCTACTGTAATGATC-3'; reverse, 5'-TTACCAGTGTCAATTATATCTTCAACAATC-3'; probe, 5'-JOE-TGAGAGATCATCTCCACCAATAACTTTTATGTCCC-TAMRA-3'.

Statistics—All data are expressed as the mean ± S.D. Comparisons of values were made using a non-parametric Mann-Whitney U test. Significance was defined as two-sided p < 0.05.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Expression of VEGF and Its Receptors by ES Cells and Up-regulation by Hypoxia—Undifferentiated wild type (WT) ES cells were found to produce detectable amounts of VEGF in normoxia, which were up-regulated when the cells were cultured in hypoxia (Table I). ES cells also produced the VEGF homologue PlGF, but its expression was not inducible by hypoxia (Fig. 1A). Hypoxic induction of VEGF was mediated via binding of HIF-1{alpha} to the HRE as both HIF-1{alpha}–/– ES cells and ES cells with a deletion of the HRE in the VEGF promoter (VEGF{partial}/{partial} ES cells) were unable to up-regulate VEGF in response to hypoxia (Table I; Fig. 1, A and B).


View this table:
[in this window]
[in a new window]
  		TABLE I
VEGF secretion by ES cells in conditioned medium

The data represent the means ± S.D. of VEGF antigen levels (pg/ml) (n = 18).

 



View larger version (61K):
[in this window]
[in a new window]
  		FIG. 1.
Effect of hypoxia on the expression of VEGF and its receptors. A, Northern blot for VEGF, VEGFR-1, VEGFR-2, Nrp-1, and PlGF in WT or HIF-1{alpha}–/– ES cells, cultured for 24 h under normoxia (N) or hypoxia (H, 0.5% O2). B, Northern blot for VEGF in WT or VEGF {partial}/{partial} ES cells, cultured under normoxia or hypoxia for 24 h.

 
The survival function of VEGF for endothelial cells is known to be mediated via VEGF receptor type-2 (VEGFR-2; also termed Flk-1 or kinase insert domain-containing receptor) (25, 26). Northern blot analysis revealed that ES cells expressed VEGFR-2 and that expression of VEGFR-2 in WT ES cells was increased in response to hypoxia (Fig. 1A). Hypoxic induction of VEGFR-2 in WT ES cells was HIF-1{alpha}-dependent, since similar expression levels were detected in HIF-1{alpha}–/– ES cells in normoxia and hypoxia (Fig. 1A). In contrast, hypoxic induction of VEGFR-1 (also termed Flt-1), was retained in HIF-1{alpha}–/– ES cells, whereas expression of PlGF, a Flt-1-specific ligand, was only slightly influenced by hypoxia (Fig. 1A). These data may reflect the differential roles of Flk-1 and Flt-1.

Nrp-1, a selective receptor for the VEGF165 isoform is known to assist Flk-1 as a co-receptor (13). Therefore, the expression and potential role of Nrp-1 in ES cell survival was studied. WT ES cells expressed Nrp-1 in normoxia, and expression of Nrp-1 was increased in response to hypoxia (Fig. 1A). Hypoxic induction of Nrp-1 was blocked in HIF-1{alpha}–/– ES cells, indicating that HIF-1{alpha} was involved (Fig. 1A).

ES Cell Apoptosis during Prolonged Hypoxia—To study whether VEGF affects survival of ES cells, we first optimized the experimental conditions to induce ES cell apoptosis. To quantify apoptosis the number of oligonucleosomes per 105 adherent cells was determined or the number of terminal deoxytransferase-mediated deoxyuridine nick end-labeling-positive cells was counted, yielding overall comparable results. ES cell apoptosis was found to be dependent on the cellular differentiation and on the duration and degree of hypoxia. When cultured in the presence of LIF, ES cells remained undifferentiated, as determined by their high nucleus-to-cytosol ratio and typical growth in small cell clumps. In contrast, when cultured for three subsequent passages without LIF, ES cells grew as monolayers of differentiated cells with flattened fibroblast-like appearance and a high cytosol-to-nucleus ratio. When undifferentiated WT ES cells were cultured for 24 h in progressively lower O2 concentrations, an increasing fraction of WT ES cells became apoptotic (Fig. 2A). In contrast, differentiated WT ES cells without LIF became resistant to apoptosis when cultured under low (0.5%) oxygen conditions for 24 h (not shown). After normoxia for 24 h, the number of oligonucleosomes per 105 cells was low (41 ± 5 with LIF and 31 ± 2 without LIF). When ES cells were cultured for 24 h at 0.5% O2, the number of oligonucleosomes per 105 cells was 340 ± 23 with LIF versus 52 ± 5 without LIF (p < 0.05 versus with LIF).



View larger version (29K):
[in this window]
[in a new window]
  		FIG. 2.
Specificity of the survival role of VEGF. Apoptosis is expressed as mean numbers of oligonucleosomes/105 cells ± S.D. (n = 6). A, exposure of WT ES cells for 24 h to decreasing concentrations of O2 resulted in a consistently increasing apoptotic response. B, apoptosis of WT ES cells, cultured in hypoxia for 48 h in the presence of vehicle (control) or neutralizing monoclonal antibodies against VEGF, bFGF, PDGF-B, IGF-1, EGF, or PlGF (100 µg/ml). Only anti-VEGF antibodies render the ES cells sensitive to apoptosis under prolonged hypoxia. C and D, apoptosis of WT ES cells cultured in hypoxia for 24 h without (control) or with supplementation of medium conditioned by WT ES cells cultured under hypoxia during 24 h (C) or 48 h (D) in the presence of buffer or of monoclonal antibodies against VEGF, bFGF, PDGF-B, IGF-1, EGF, or PlGF (100 µg/ml). Only VEGF antibodies block the survival activity in the conditioned medium. E, WT ES cells were incubated for 24 h in 0.5% O2 and treated with various concentrations of VEGF, PlGF, bFGF, EGF, IGF-1, or PDGF-BB or with vehicle (control). Only VEGF and bFGF, but not PlGF, EGF, IGF-1 or PDGF-BB, mediated ES cell survival during hypoxia.

 
Interestingly, ES cell apoptosis was also dependent on the duration of the hypoxic stress. Based on the finding that a fraction of undifferentiated WT ES cells became apoptotic when exposed to 0.5% O2 for 24 h, we had anticipated that longer periods of hypoxia would even further aggravate ES cell apoptosis. Surprisingly, however, the residual ES cells, which were still viable after 24 h of hypoxia, became resistant to apoptosis when stressed for another 24 h of hypoxia (i.e. from 24 to 48 h; phase B; Fig. 3A, solid line). This was not due to ES cell differentiation, as the colony morphology typical for undifferentiated cultures was retained. These data, therefore, indicate that a survival mechanism rescued the residual ES cells during prolonged hypoxia.



View larger version (36K):
[in this window]
[in a new window]
  		FIG. 3.
ES cell apoptosis and survival during short (24 h) and long term (48 h) hypoxia. Apoptosis is expressed as mean numbers of oligonucleosomes/105 cells ± S.D. (n = 6). A, WT ES cells exhibit apoptosis up to 24 h of hypoxia (0.5% O2) but subsequently become refractory and survive prolonged hypoxia (up to 48 h; solid line). Supplementation of VEGF (50 nM) suppresses apoptosis (gray line), whereas ES cells remain sensitive to apoptosis during prolonged hypoxia in the presence of a monoclonal anti-VEGF antibody (100 µg/ml; dotted line). B–D, apoptosis of VEGF–/– cells (B), PlGF–/– cells (C), and VEGF{delta}/{delta} cells (D)(dotted lines) with their respective WT control cells (solid lines) in response to normoxia (N) or hypoxia (H, 0.5% O2). Loss of VEGF expression (VEGF–/– cells; (B)) or of hypoxic induction of VEGF expression (VEGF{delta}/{delta} cells; (D)) causes ES cells to remain sensitive to apoptosis during prolonged hypoxia.

 
Role of VEGF in ES Cell Survival during Prolonged Hypoxia; Pharmacological Evidence—Because VEGF functions as a survival factor for various cell types and is strongly induced by hypoxia in ES cells, we examined whether survival of WT ES cells under prolonged hypoxia was related to the hypoxic induction of VEGF. Supplementation of various neutralizing antibodies to the culture medium of WT ES cells, which were grown under hypoxia for 48 h, revealed that only anti-VEGF antibodies prevented survival of ES cells and maintained apoptosis during prolonged hypoxia (i.e. between 24 and 48 h) (Fig. 2B and Fig. 3A, dotted line). In contrast, antibodies against bFGF, PDGF-BB, EGF, IGF-1, or PlGF did not affect apoptosis (Fig. 2B), indicating that the survival activity was mediated by VEGF. Furthermore, apoptosis of WT ES cells cultured under hypoxia for 24 h was prevented by supplementation of culture medium, conditioned by WT ES cells under hypoxia for 24 h or for 48 h (Fig. 2, C and D), indicating that the survival factor VEGF was secreted in the medium at significant amounts already after 24 h of hypoxia. Accordingly, only anti-VEGF antibodies inhibited the survival activity present in culture medium, conditioned by WT ES cells under hypoxia for 24 or 48 h (Fig. 2, C and D), confirming that VEGF was the survival factor secreted in the culture medium. Antibodies against bFGF, PDGF-BB, EGF, IGF-1, or PlGF did not inhibit the survival activity in culture medium, conditioned by WT ES cells under hypoxia for 24 or 48 h (Fig. 2, C–D).

Moreover, recombinant VEGF165 inhibited apoptosis of WT ES cells both during short term (<24 h) and prolonged (>24 h) hypoxia, indicating that the VEGF-mediated survival signals overruled the death pathway in response to acute hypoxia (Figs. 3A, gray line and 2E). In contrast, the addition of recombinant PDGF-BB, EGF, IGF-1, or PlGF (Fig. 2E) was ineffective. Recombinant bFGF also rendered ES cells refractory to hypoxia-induced apoptosis, similarly as observed for VEGF (Fig. 2E). However, antibodies against bFGF did not affect survival of ES cells cultured under hypoxic conditions for 24 h with culture medium conditioned by ES cells under hypoxia for 24 h (Fig. 2C), whereas these antibodies also did not inhibit survival of ES cells cultured under hypoxia with medium conditioned by ES cells under hypoxia for 48 h (Fig. 2D). Therefore, endogenous bFGF is unlikely to contribute to the survival of ES cells during short term (<24 h) or during prolonged hypoxia (>24 h). Conversely, an immunoneutralizing antibody to VEGF maintained susceptibility of WT ES cells to apoptosis beyond 24 h of hypoxia (Fig. 3A; dotted line). These findings together with the observation that WT ES cells became refractory to apoptosis after 24 h of hypoxia suggested that VEGF was only produced at significant levels beyond 24 h. VEGF was indeed secreted at high levels by WT ES cells beyond 24 h and remained highly expressed during 48 h (Table I). Consistent with its inability to affect ES cell apoptosis during hypoxia, PlGF expression was not induced by hypoxia (Fig. 1A).

Role of VEGF in ES Cell Survival during Prolonged Hypoxia; Genetic Evidence—To extend the VEGF immunoneutralization data, apoptosis was studied in ES cells lacking VEGF (VEGF–/–). VEGF–/– ES cells became apoptotic in response to short term hypoxia (<24 h), but in contrast to WT ES cells VEGF–/– ES cells remained susceptible to apoptosis up to 48 h of hypoxia, most likely because they did not produce the survival factor VEGF (Fig. 3B). The survival activity of VEGF was specific, as PlGF-deficient (PlGF–/–) ES cells became apoptotic in response to 24 h of hypoxia, but like WT ES cells PlGF–/– ES cells became refractory to hypoxia-induced apoptosis upon prolonged hypoxia (48 h) (Fig. 3C). The lack of an effect of PlGF on apoptosis in WT cells was not due to absent PlGF expression (Fig. 1A).

Genetic Evidence for a HIF-1{alpha} -> HRE -> VEGF Survival Pathway during Prolonged Hypoxia—HIF-1{alpha}–/– ES cells were unable to up-regulate VEGF in response to hypoxia, consistent with the observation that hypoxic induction of VEGF expression is mediated by HIF-1{alpha}, more particularly via binding of HIF-1{alpha} to a specific HRE in the VEGF promoter (27). ES cells in which the HRE in the VEGF promoter was mutated by gene targeting (VEGF{partial}/{partial}) could indeed not up-regulate VEGF expression in response to hypoxia (15), similarly to the lack of hypoxic up-regulation of VEGF in HIF-1{alpha}–/– ES cells (Table I; Fig. 1B). VEGF{partial}/{partial} ES cells became apoptotic during the first 24 h of hypoxia, and like VEGF–/– ES cells, remained sensitive to apoptosis during prolonged hypoxia (up to 48 h; Fig. 3D).

Role of Neuropilin-1 in Survival of ES Cells during Hypoxic Stress—To study whether Nrp-1 plays a role in cell survival, WT ES cells were stably transfected with a plasmid containing the human NRP-1 gene (NRP-1+ ES cells), resulting in 30-fold higher NRP-1 expression levels than in WT ES cells transfected with a control plasmid (mRNA copies per 100 mRNA copies of hypoxanthine guanine phosphoribosyltransferase: 0.86 ± 0.03 for WT ES cells versus 27 ± 6 for NRP-1+ ES cells, p < 0.05 by Mann-Whitney U test, n = 6). Because we anticipated that NRP-1 would enhance the VEGF-dependent survival effect, apoptosis of WT and NRP-1+ ES cells was studied at 24 h of hypoxia, i.e. at a time when VEGF levels were half-maximally elevated (Table I). NRP-1 expression levels determined the survival response of WT ES cells in hypoxia, since ES cells overexpressing human NRP-1 were more resistant to hypoxic stress than mock-transfected clones. The oligonucleosomes per 105 ES cells after 24 h were 35 ± 4 for WT cells versus 40 ± 2 for NRP-1+ ES cells in normoxia (p = not significant) and 340 ± 21 for WT cells versus 110 ± 9 for NRP-1+ ES cells in hypoxia (p < 0.05; n = 6).


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
Cells deprived of oxygen are at risk for irreversible damage and even death. In many cases hypoxic cells will up-regulate angiogenic factors that stimulate the formation of new blood vessels to restore oxygenation, but alternative mechanisms may secure the viability of the ischemic cells before onset of angiogenesis, a process that requires at least several days. In this study we provide evidence that the angiogenic factor VEGF contributes to the survival of ES cells independently of angiogenesis, likely by directly activating VEGFR-2 on ES cells. Such a dual survival activity of VEGF, via a direct trophic effect on the target cell and via an indirect effect on blood vessels, has been documented for motor neurons (15–17). For ES cells, which have to survive the hypoxic environment in the oviduct and uterus, VEGF may not only enable the implanting embryo to immediately induce angiogenesis at the implantation site (28) but may also contribute to securing proper development before onset of vascularization after implantation of the embryo in the uterine wall. Blastocyst-stage embryos are particularly vulnerable to hypoxic damage before they implant in the vascularized uterine tissue, and early hypoxia was shown to have a devastating impact on implantation and embryonic development in mice and rats (1, 29, 30). This is indeed a critical stage of development as the pluripotential undifferentiated embryonic stem cells, from which all lineages subsequently differentiate, develop in the inner cell mass in the blastocyst just before implantation. Survival of ES cells not only is of utmost importance for normal development in vivo but also for safe manipulation and proper differentiation in vitro. Examples of applications involving the handling of ES cells and preimplantation embryos in stressful conditions include in vitro fertilization procedures, morula and blastocyst manipulation for transgenesis in experimental animal models, and in vitro embryo culture. ES cells also constitute a potential renewable source of more differentiated progenitors for tissue regeneration via cellular transplantation (21, 22). Surprisingly, however, little is known about the mechanisms regulating survival of ES cells and preimplantation embryos in stressful conditions such as hypoxia.

We previously demonstrated that ES cells undergo apoptosis in response to short term hypoxia for less than 24 h (23). Here, we provide novel findings that this cell death pathway is overruled by a survival pathway during prolonged hypoxia (48 h) and that this involves HIF-1{alpha}-dependent up-regulation of VEGF which, in an autocrine action involving VEGFR-2 and Nrp-1, protects against apoptosis.

VEGF, the prototypic angiogenic factor, is a survival factor for ES cells, as supplementation of exogenous VEGF165 prevented apoptosis in response to both short (<24 h) and long term hypoxia (>24 h). In addition, apoptosis was sustained during prolonged hypoxia (i) when ES cells were treated with anti-VEGF antibodies, (ii) when ES cells lacked VEGF (VEGF–/–), or (iii) when ES cells were unable to up-regulate VEGF during hypoxia as a result of targeted mutation of the HIF-1{alpha} binding site (VEGF{delta}/{delta}). The survival effect was specific for VEGF as ES cells lacking PlGF (PlGF–/–) or WT ES cells treated with antibodies against bFGF, PDGF-BB, EGF, IGF-1, or PlGF survived prolonged hypoxia. Interestingly, supplementation of recombinant bFGF also rescued WT ES cells from hypoxia-induced apoptosis. However, several studies have demonstrated that expression of VEGF but not of bFGF is enhanced during hypoxia in various cell types and tissues (31–34). Furthermore, we observed that the addition of antibodies against bFGF did not increase apoptosis of ES cells during short term hypoxia or during prolonged hypoxia. Therefore, it may be concluded that endogenous bFGF most likely does not contribute to the survival response of ES cells during hypoxic stress. Taken together our data clearly demonstrate an important role for VEGF as a survival factor for ES cells during hypoxic stress.

Several growth factors and cytokines previously have been demonstrated to exhibit similar protective effects against hypoxia-induced apoptosis for other cell types but not yet for ES cells. Indeed, a survival activity has been documented for bFGF, PDGF-B, VEGF, nerve growth factor, brain-derived neurotrophic factor, neurotrophin-3 and erythropoietin for hypoxic neurons (15, 35–41), acidic fibroblast growth factor, IGF-I and erythropoietin for hypoxic myocardial cells (42–46), VEGF for hypoxic chondrocytes (47), or hepatocyte growth factor and erythropoietin for hypoxic renal cells (48, 49). Growth factors may also protect cells against apoptosis in response to other stimuli, as exemplified by the ability of erythropoietin, c-kit ligand, or interleukin-3 to block p53-mediated apoptosis of hematopoietic cell lines (50–52) by the protective effect of IGF-I or EGF on epithelial cells or lymphocytes against Fas-induced apoptosis (53–55) or by the inhibition by IGF-I of glutamate-induced apoptosis of oligodendrocyte progenitors (56). In addition, IGF-1 and PDGF inhibit apoptosis of fibroblasts during serum starvation (57), whereas VEGF protects HepG2 and endothelial cells against apoptosis induced by TNF-{alpha} or serum deprivation (25, 58). Furthermore, chronic hypoxia in the lung not only protects smooth muscle cells from apoptosis but can even stimulate these cells to replicate possibly via induction by PDGF-B and endothelin-1, which are secreted by endothelial cells (59, 60).

VEGFR-2 has been documented on hemangioblasts, smooth muscle cells, placental trophoblasts, pulmonary epithelial cells, Schwann cells, non-endothelial embryonic cells, and motor neurons (61, 62). Its expression was also documented in undifferentiated ES cells (63–66). Our present findings indicate that VEGFR-2 is expressed in ES cells and that its expression is induced by hypoxia via a HIF-1{alpha}-dependent pathway. Because VEGF induces survival signals in endothelial cells via activation of VEGFR-2 (25), VEGFR-2 is a likely candidate to mediate the survival function of VEGF in ES cells. VEGFR-1 is less likely to be implicated in survival of ES cells since its expression is only minimally regulated by HIF-1{alpha} and its ligand PlGF failed to protect ES cells against apoptosis.

Nrp-1 has been implicated in endothelial migration as a co-receptor for VEGFR-2, and accumulating data suggest its possible role in VEGF-dependent survival in adult cells including endothelial, neuronal, and tumor cells (11, 15, 67–69). However, involvement of Nrp-1 in survival of ES cells had not been documented yet. Our findings revealed that overexpression of human NRP-1 in WT ES cells decreased apoptosis in response to hypoxia, which up-regulates VEGF (see Fig. 1A and Table I). Because survival during prolonged hypoxia depended on VEGF, NRP-1 likely enhanced the VEGF-survival effect as a co-receptor of VEGFR-2. Overexpression of NRP-1 may have enabled ES cells to respond to lower levels of VEGF, which were insufficient to protect WT ES cells against apoptosis during initial hypoxia. Because neuropilin-1 only has a short intracellular domain and cannot transduce intracellular signals by itself, it has been suggested that complex formation of NRP-1 with a co-receptor is necessary for signal transduction (12, 70). The VEGF-dependent survival signaling is assumed to be mediated via the VEGFR-2; however, NRP-1 may also mediate a VEGF survival response independent of VEGFR-2, since VEGF was able to induce survival of NRP-1-expressing tumor cells and podocytes that did not express VEGFR-2 (71, 72).

In conclusion, our results show that hypoxic stress in ES cells is characterized by HIF-1{alpha}-dependent up-regulation of VEGF and its receptors VEGFR-2 and Nrp-1 and reveal a beneficial effect of Nrp-1 on the survival response of ES cells in hypoxia and a novel role for VEGF as an autocrine survival factor for ES cells during prolonged hypoxic conditions.


   FOOTNOTES
 
* This work was supported by a postdoctoral fellowship from the Fund for Scientific Research-Flanders (Belgium) (FWO) (to K. B.) and European Union Grant BIOMED BMH4-CT98-3380 (to P. C. and D. C.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

To whom correspondence should be addressed: Center for Transgene Technology and Gene Therapy, VIB, KULeuven, Campus Gasthuisberg, Herestraat 49 bus 912, B-3000, Leuven, Belgium. Tel.: 32-16-34-57-75; Fax: 32-16-34-59-90; E-mail: mieke.dewerchin{at}med.kuleuven.ac.be.

1 The abbreviations used are: VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor; bFGF, basic fibroblast growth factor (FGF); EGF, epidermal growth factor; ES cell, embryonic stem cell; Flk-1, fetal liver kinase-1; Flt-1, fms-like tyrosine kinase-1; HIF, hypoxia-inducible factor; HRE, hypoxia-response element; IGF, insulin-like growth factor; LIF, leukemia inhibitory factor; NRP-1, neuropilin-1; PDGF, platelet-derived growth factor; PlGF, placenta growth factor; WT, wild type. Back


   ACKNOWLEDGMENTS
 
We thank K. Bijnens, E. Gils, S. Jansen, Leen Notebaert, T. Vancoetsem, A. Vandenhoeck, S. Wyns (Center for Transgene Technology and Gene Therapy, Leuven, Belgium), and I. Lamarche and P. Rigon (Sanofi~Aventis Recherche, Toulouse, France) for technical assistance.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Blackburn, R. O., and Clegg, E. J. (1979) Teratology 20, 441–446[Medline] [Order article via Infotrieve]
  2. Graham, C. H., Postovit, L. M., Park, H., Canning, M. T., and Fitzpatrick, T. E. (2000) Placenta 21, 443–450[CrossRef][Medline] [Order article via Infotrieve]
  3. Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., Declercq, C., Pawling, J., Moons, L., Collen, D., Risau, W., and Nagy, A. (1996) Nature 380, 435–439[CrossRef][Medline] [Order article via Infotrieve]
  4. Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K. S., Powell-Braxton, L., Hillan, K. J., and Moore, M. W. (1996) Nature 380, 439–442[CrossRef][Medline] [Order article via Infotrieve]
  5. Carmeliet, P. (2003) Nat. Med. 9, 653–660[CrossRef][Medline] [Order article via Infotrieve]
  6. Neufeld, G., Cohen, T., Gitay-Goren, H., Poltorak, Z., Tessler, S., Sharon, R., Gengrinovitch, S., and Levi, B. Z. (1996) Cancer Metastasis Rev. 15, 153–158[CrossRef][Medline] [Order article via Infotrieve]
  7. Neufeld, G., Cohen, T., Gengrinovitch, S., and Poltorak, Z. (1999) FASEB J. 13, 9–22[Abstract/Free Full Text]
  8. Carmeliet, P., Ng, Y. S., Nuyens, D., Theilmeier, G., Brusselmans, K., Cornelissen, I., Ehler, E., Kakkar, V. V., Stalmans, I., Mattot, V., Perriard, J. C., Dewerchin, M., Flameng, W., Nagy, A., Lupu, F., Moons, L., Collen, D., D'Amore, P. A., and Shima, D. T. (1999) Nat. Med. 5, 495–502[CrossRef][Medline] [Order article via Infotrieve]
  9. Stalmans, I., Ng, Y. S., Rohan, R., Fruttiger, M., Bouche, A., Yuce, A., Fujisawa, H., Hermans, B., Shani, M., Jansen, S., Hicklin, D., Anderson, D. J., Gardiner, T., Hammes, H. P., Moons, L., Dewerchin, M., Collen, D., Carmeliet, P., and D'Amore, P. A. (2002) J. Clin. Investig. 109, 327–336[CrossRef][Medline] [Order article via Infotrieve]
  10. Stalmans, I., Lambrechts, D., De Smet, F., Jansen, S., Wang, J., Maity, S., Kneer, P., von der Ohe, M., Swillen, A., Maes, C., Gewillig, M., Molin, D. G., Hellings, P., Boetel, T., Haardt, M., Compernolle, V., Dewerchin, M., Plaisance, S., Vlietinck, R., Emanuel, B., Gittenberger-de Groot, A. C., Scambler, P., Morrow, B., Driscol, D. A., Moons, L., Esguerra, C. V., Carmeliet, G., Behn-Krappa, A., Devriendt, K., Collen, D., Conway, S. J., and Carmeliet, P. (2003) Nat. Med. 9, 173–182[CrossRef][Medline] [Order article via Infotrieve]
  11. Soker, S., Takashima, S., Miao, H. Q., Neufeld, G., and Klagsbrun, M. (1998) Cell 92, 735–745[CrossRef][Medline] [Order article via Infotrieve]
  12. Neufeld, G., Cohen, T., Shraga, N., Lange, T., Kessler, O., and Herzog, Y. (2002) Trends Cardiovasc. Med. 12, 13–19[CrossRef][Medline] [Order article via Infotrieve]
  13. Yamada, Y., Oike, Y., Ogawa, H., Ito, Y., Fujisawa, H., Suda, T., and Takakura, N. (2003) Blood 101, 1801–1809[Abstract/Free Full Text]
  14. Semenza, G. L. (2000) Biochem. Pharmacol. 59, 47–53[CrossRef][Medline] [Order article via Infotrieve]
  15. Oosthuyse, B., Moons, L., Storkebaum, E., Beck, H., Nuyens, D., Brusselmans, K., Van Dorpe, J., Hellings, P., Gorselink, M., Heymans, S., Theilmeier, G., Dewerchin, M., Laudenbach, V., Vermylen, P., Raat, H., Acker, T., Vleminckx, V., Van Den Bosch, L., Cashman, N., Fujisawa, H., Drost, M. R., Sciot, R., Bruyninckx, F., Hicklin, D. J., Ince, C., Gressens, P., Lupu, F., Plate, K. H., Robberecht, W., Herbert, J. M., Collen, D., and Carmeliet, P. (2001) Nat. Genet. 28, 131–138[CrossRef][Medline] [Order article via Infotrieve]
  16. Jin, K. L., Mao, X. O., and Greenberg, D. A. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 10242–10247[Abstract/Free Full Text]
  17. Azzouz, M., Ralph, G. S., Storkebaum, E., Walmsley, L. E., Mitrophanous, K. A., Kingsman, S. M., Carmeliet, P., and Mazarakis, N. D. (2004) Nature 429, 413–417[CrossRef][Medline] [Order article via Infotrieve]
  18. Rabbany, S. Y., Heissig, B., Hattori, K., and Rafii, S. (2003) Trends Mol. Med. 9, 109–117[CrossRef][Medline] [Order article via Infotrieve]
  19. Schuch, G., Heymach, J. V., Nomi, M., Machluf, M., Force, J., Atala, A., Eder, J. P., Jr., Folkman, J., and Soker, S. (2003) Cancer Res. 63, 8345–8350[Abstract/Free Full Text]
  20. Wang, C., Jiao, C., Hanlon, H. D., Zheng, W., Tomanek, R. J., and Schatteman, G. C. (2004) Am. J. Physiol. Heart Circ. Physiol. 286, 1985–1993
  21. Czyz, J., Wiese, C., Rolletschek, A., Blyszczuk, P., Cross, M., and Wobus, A. M. (2003) Biol. Chem. 384, 1391–1409[CrossRef][Medline] [Order article via Infotrieve]
  22. Sylvester, K. G., and Longaker, M. T. (2004) Arch. Surg. 139, 93–99[Abstract/Free Full Text]
  23. Carmeliet, P., Dor, Y., Herbert, J. M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., Koch, C. J., Ratcliffe, P., Moons, L., Jain, R. K., Collen, D., Keshert, E., and Keshet, E. (1998) Nature 394, 485–490[CrossRef][Medline] [Order article via Infotrieve]
  24. Carmeliet, P., Moons, L., Luttun, A., Vincenti, V., Compernolle, V., De Mol, M., Wu, Y., Bono, F., Devy, L., Beck, H., Scholz, D., Acker, T., DiPalma, T., Dewerchin, M., Noel, A., Stalmans, I., Barra, A., Blacher, S., Vandendriessche, T., Ponten, A., Eriksson, U., Plate, K. H., Foidart, J. M., Schaper, W., Charnock-Jones, D. S., Hicklin, D. J., Herbert, J. M., Collen, D., and Persico, M. G. (2001) Nat. Med. 7, 575–583[CrossRef][Medline] [Order article via Infotrieve]
  25. Gerber, H. P., McMurtrey, A., Kowalski, J., Yan, M., Keyt, B. A., Dixit, V., and Ferrara, N. (1998) J. Biol. Chem. 273, 30336–30343[Abstract/Free Full Text]
  26. Schlessinger, J. (2000) Cell 103, 211–225[CrossRef][Medline] [Order article via Infotrieve]
  27. Maxwell, P. H., and Ratcliffe, P. J. (2002) Semin. Cell Dev. Biol. 13, 29–37[CrossRef][Medline] [Order article via Infotrieve]
  28. Krussel, J. S., Behr, B., Milki, A. A., Hirchenhain, J., Wen, Y., Bielfeld, P., and Lake Polan, M. (2001) Mol. Hum. Reprod. 7, 57–63[Abstract/Free Full Text]
  29. Checiu, M., and Checiu, I. (1993) Rom. J. Morphol. Embryol. 39, 87–91[Medline] [Order article via Infotrieve]
  30. Rattner, B. A., and Ramm, G. M. (1975) Aviat. Space Environ. Med. 46, 911–915[Medline] [Order article via Infotrieve]
  31. Hata, Y., Nakagawa, K., Ishibashi, T., Inomata, H., Ueno, H., and Sueishi, K. (1995) Virchows Arch. 426, 479–486[Medline] [Order article via Infotrieve]
  32. Fang, J., Yan, L., Shing, Y., and Moses, M. A. (2001) Cancer Res. 61, 5731–5735[Abstract/Free Full Text]
  33. Brogi, E., Wu, T., Namiki, A., and Isner, J. M. (1994) Circulation 90, 649–652[Abstract/Free Full Text]
  34. Ishibashi, H., Shiratuchi, T., Nakagawa, K., Onimaru, M., Sugiura, T., Sueishi, K., and Shirasuna, K. (2001) Oral Oncol. 37, 77–83[CrossRef][Medline] [Order article via Infotrieve]
  35. Akaneya, Y., Enokido, Y., Takahashi, M., and Hatanaka, H. (1993) J. Cereb. Blood Flow Metab. 13, 1029–1032[Medline] [Order article via Infotrieve]
  36. Hayashi, T., Abe, K., and Itoyama, Y. (1998) J. Cereb. Blood Flow Metab. 18, 887–895[CrossRef][Medline] [Order article via Infotrieve]
  37. Holtzman, D. M., Sheldon, R. A., Jaffe, W., Cheng, Y., and Ferriero, D. M. (1996) Ann. Neurol. 39, 114–122[CrossRef][Medline] [Order article via Infotrieve]
  38. Han, M. K., Kim, M., Bae, S. Y., Kang, L., Han, S. Y., Lee, Y. S., Rha, J. H., Kim, S. U., and Roh, J. K. (2004) Neuroreport 15, 847–850[CrossRef][Medline] [Order article via Infotrieve]
  39. Zhang, S. X., Gozal, D., Sachleben, L. R., Jr., Rane, M., Klein, J. B., and Gozal, E. (2003) FASEB J. 17, 1709–1711[Abstract/Free Full Text]
  40. Kim, D. H., Zhao, X., Tu, C. H., Casaccia-Bonnefil, P., and Chao, M. V. (2004) J. Neurosurg. 100, 79–87[Medline] [Order article via Infotrieve]
  41. Wang, C. H., Liang, C. L., Huang, L. T., Liu, J. K., Hung, P. H., Sun, A., and Hung, K. S. (2004) Biochem. Biophys. Res. Commun. 314, 1064–1071[Medline] [Order article via Infotrieve]
  42. Htun, P., Ito, W. D., Hoefer, I. E., Schaper, J., and Schaper, W. (1998) J. Mol. Cell. Cardiol. 30, 867–877[CrossRef][Medline] [Order article via Infotrieve]
  43. Cai, Z., Manalo, D. J., Wei, G., Rodriguez, E. R., Fox-Talbot, K., Lu, H., Zweier, J. L., and Semenza, G. L. (2003) Circulation 108, 79–85[Abstract/Free Full Text]
  44. Chao, W., Matsui, T., Novikov, M. S., Tao, J., Li, L., Liu, H., Ahn, Y., and Rosenzweig, A. (2003) J. Gene Med. 5, 277–286[CrossRef][Medline] [Order article via Infotrieve]
  45. Tramontano, A. F., Muniyappa, R., Black, A. D., Blendea, M. C., Cohen, I., Deng, L., Sowers, J. R., Cutaia, M. V., and El-Sherif, N. (2003) Biochem. Biophys. Res. Commun. 308, 990–994[CrossRef][Medline] [Order article via Infotrieve]
  46. Parsa, C. J., Kim, J., Riel, R. U., Pascal, L. S., Thompson, R. B., Petrofski, J. A., Matsumoto, A., Stamler, J. S., and Koch, W. J. (2004) J. Biol. Chem. 279, 20655–20662[Abstract/Free Full Text]
  47. Maes, C., Stockmans, I., Moermans, K., Van Looveren, R., Smets, N., Carmeliet, P., Bouillon, R., and Carmeliet, G. (2004) J. Clin. Investig. 113, 188–199[CrossRef][Medline] [Order article via Infotrieve]
  48. de Souza Durao, M., Jr., Razvickas, C. V., Goncalves, E. A., Okano, I. R., Camargo, S. M., Monte, J. C., and dos Santos, O. F. (2003) Ren. Fail. 25, 341–353[CrossRef][Medline] [Order article via Infotrieve]
  49. Vesey, D. A., Cheung, C., Pat, B., Endre, Z., Gobe, G., and Johnson, D. W. (2004) Nephrol. Dial. Transplant. 19, 348–355[Abstract/Free Full Text]
  50. Canman, C. E., Gilmer, T. M., Coutts, S. B., and Kastan, M. B. (1995) Genes Dev. 9, 600–611[Abstract/Free Full Text]
  51. Lin, Y., and Benchimol, S. (1995) Mol. Cell. Biol. 15, 6045–6054[Abstract]
  52. Quelle, F. W., Wang, J., Feng, J., Wang, D., Cleveland, J. L., Ihle, J. N., and Zambetti, G. P. (1998) Genes Dev. 12, 1099–1107[Abstract/Free Full Text]
  53. Gibson, S., Tu, S., Oyer, R., Anderson, S. M., and Johnson, G. L. (1999) J. Biol. Chem. 274, 17612–17618[Abstract/Free Full Text]
  54. Walsh, P. T., Smith, L. M., and O'Connor, R. (2002) Immunology 107, 461–471[CrossRef][Medline] [Order article via Infotrieve]
  55. Musallam, L., Ethier, C., Haddad, P. S., and Bilodeau, M. (2004) J. Cell. Physiol. 198, 62–72[CrossRef][Medline] [Order article via Infotrieve]
  56. Ness, J. K., Scaduto, R. C., Jr., and Wood, T. L. (2004) Glia 46, 183–194[CrossRef][Medline] [Order article via Infotrieve]
  57. Harrington, E. A., Bennett, M. R., Fanidi, A., and Evan, G. I. (1994) EMBO J. 13, 3286–3295[Medline] [Order article via Infotrieve]
  58. Baek, J. H., Jang, J. E., Kang, C. M., Chung, H. Y., Kim, N. D., and Kim, K. W. (2000) Oncogene 19, 4621–4631[CrossRef][Medline] [Order article via Infotrieve]
  59. Kourembanas, S., Morita, T., Liu, Y., and Christou, H. (1997) Kidney Int. 51, 438–443[Medline] [Order article via Infotrieve]
  60. Minamino, T., Mitsialis, S. A., and Kourembanas, S. (2001) Mol. Cell. Biol. 21, 3336–3342[Abstract/Free Full Text]
  61. Kubo, H., and Alitalo, K. (2003) Genes Dev. 17, 322–329[Free Full Text]
  62. Cross, M. J., Dixelius, J., Matsumoto, T., and Claesson-Welsh, L. (2003) Trends Biochem. Sci. 28, 488–494[CrossRef][Medline] [Order article via Infotrieve]
  63. Sone, M., Itoh, H., Yamashita, J., Yurugi-Kobayashi, T., Suzuki, Y., Kondo, Y., Nonoguchi, A., Sawada, N., Yamahara, K., Miyashita, K., Park, K., Shibuya, M., Nito, S., Nishikawa, S., and Nakao, K. (2003) Circulation 107, 2085–2088[Abstract/Free Full Text]
  64. Kaufman, D. S., Hanson, E. T., Lewis, R. L., Auerbach, R., and Thomson, J. A. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 10716–10721[Abstract/Free Full Text]
  65. Levenberg, S., Golub, J. S., Amit, M., Itskovitz-Eldor, J., and Langer, R. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 4391–4396[Abstract/Free Full Text]
  66. Robertson, S. M., Kennedy, M., Shannon, J. M., and Keller, G. (2000) Development 127, 2447–2459[Abstract]
  67. Bachelder, R. E., Wendt, M. A., and Mercurio, A. M. (2002) Cancer Res. 62, 7203–7206[Abstract/Free Full Text]
  68. Miao, H. Q., Lee, P., Lin, H., Soker, S., and Klagsbrun, M. (2000) FASEB J. 14, 2532–2539[Abstract/Free Full Text]
  69. Gagnon, M. L., Bielenberg, D. R., Gechtman, Z., Miao, H. Q., Takashima, S., Soker, S., and Klagsbrun, M. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 2573–2578[Abstract/Free Full Text]
  70. Nakamura, F., Kalb, R. G., and Strittmatter, S. M. (2000) J. Neurobiol. 44, 219–229[CrossRef][Medline] [Order article via Infotrieve]
  71. Bachelder, R. E., Crago, A., Chung, J., Wendt, M. A., Shaw, L. M., Robinson, G., and Mercurio, A. M. (2001) Cancer Res. 61, 5736–5740[Abstract/Free Full Text]
  72. Foster, R. R., Hole, R., Anderson, K., Satchell, S. C., Coward, R. J., Mathieson, P. W., Gillatt, D. A., Saleem, M. A., Bates, D. O., and Harper, S. J. (2003) Am. J. Physiol. Renal Physiol. 284, 1263–1273

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Cell Physiol.Home page
S. H. Lee, M. H. Kim, and H. J. Han
Arachidonic acid potentiates hypoxia-induced VEGF expression in mouse embryonic stem cells: involvement of Notch, Wnt, and HIF-1{alpha}
Am J Physiol Cell Physiol, July 1, 2009; 297(1): C207 - C216.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C.-H. Jeong, H.-J. Lee, J.-H. Cha, J. H. Kim, K. R. Kim, J.-H. Kim, D.-K. Yoon, and K.-W. Kim
Hypoxia-inducible Factor-1{alpha} Inhibits Self-renewal of Mouse Embryonic Stem Cells in Vitro via Negative Regulation of the Leukemia Inhibitory Factor-STAT3 Pathway
J. Biol. Chem., May 4, 2007; 282(18): 13672 - 13679.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
J.-Y. Liou, D. P. Ellent, S. Lee, J. Goldsby, B.-S. Ko, N. Matijevic, J.-C. Huang, and K. K. Wu
Cyclooxygenase-2-Derived Prostaglandin E2 Protects Mouse Embryonic Stem Cells from Apoptosis
Stem Cells, May 1, 2007; 25(5): 1096 - 1103.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
T. Wada, J. J. Haigh, M. Ema, S. Hitoshi, R. Chaddah, J. Rossant, A. Nagy, and D. van der Kooy
Vascular endothelial growth factor directly inhibits primitive neural stem cell survival but promotes definitive neural stem cell survival.
J. Neurosci., June 21, 2006; 26(25): 6803 - 6812.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. Okuyama, B. Krishnamachary, Y. F. Zhou, H. Nagasawa, M. Bosch-Marce, and G. L. Semenza
Expression of Vascular Endothelial Growth Factor Receptor 1 in Bone Marrow-derived Mesenchymal Cells Is Dependent on Hypoxia-inducible Factor 1
J. Biol. Chem., June 2, 2006; 281(22): 15554 - 15563.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
M. Ferrarini, N. Arsic, F. A. Recchia, L. Zentilin, S. Zacchigna, X. Xu, A. Linke, M. Giacca, and T. H. Hintze
Adeno-Associated Virus-Mediated Transduction of VEGF165 Improves Cardiac Tissue Viability and Functional Recovery After Permanent Coronary Occlusion in Conscious Dogs
Circ. Res., April 14, 2006; 98(7): 954 - 961.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
D. L. M. van der Meer, G. E. E. J. M. van den Thillart, F. Witte, M. A. G. de Bakker, J. Besser, M. K. Richardson, H. P. Spaink, J. T. D. Leito, and C. P. Bagowski
Gene expression profiling of the long-term adaptive response to hypoxia in the gills of adult zebrafish
Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2005; 289(5): R1512 - R1519.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
M. Kucia, R. Reca, K. Miekus, J. Wanzeck, W. Wojakowski, A. Janowska-Wieczorek, J. Ratajczak, and M. Z. Ratajczak
Trafficking of Normal Stem Cells and Metastasis of Cancer Stem Cells Involve Similar Mechanisms: Pivotal Role of the SDF-1-CXCR4 Axis
Stem Cells, August 1, 2005; 23(7): 879 - 894.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/5/3493    most recent
M406613200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brusselmans, K.
Right arrow Articles by Dewerchin, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brusselmans, K.
Right arrow Articles by Dewerchin, M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement